MOLECULAR MECHANISMS OF RESISTANCE OF ENDOMETRIAL HYPERPLASIA TO PROGESTAGEN THERAPY

MOLECULAR MECHANISMS OF RESISTANCE OF ENDOMETRIAL HYPERPLASIA TO PROGESTAGEN THERAPY DOI: https://doi.org/10.36074/grail-of-science.17.03.2023.076Summary The problem of resistance of atypical endometrial hyperplasia (AGE) to traditionally accepted, pathogenetically justified therapy with various types of progestins remains unsolved today. In approximately 17-20% of cases, there is a recurrence or even progression to atypical hyperplasia of the endometrium, which requires the use of surgical methods of treatment. The aim of the study was to review the literature sources to clarify the reasons for the resistance of endometrial hyperplasia without atypia to hormone therapy with different types of progestins in women with different types of estrogen and progesterone receptor expression in combination with the expression of the intercellular adhesion molecules E-cadherin and β-catenin. Downloads Downloads References Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia [Internet]. J Gynecol Oncol. 2016 Jan;27(1):e8. doi: 10.3802/jgo.2016.27.e8. Epub 2015 Dec 1. PMID: 26463434; PMCID: PMC4695458. DOI: https://doi.org/10.3802/jgo.2016.27.e8 Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia [Internet]. Hum Reprod Update. 2017 Mar 1;23(2):232-254. doi: 10.1093/humupd/dmw042. PMID: 27920066; PMCID: PMC5850217. DOI: https://doi.org/10.1093/humupd/dmw042 Yang YF, Liao YY, Peng NF, Li LQ, Xie SR, Wang RB. Prediction of coexistent carcinomas risks by subjective EIN diagnosis and comparison with WHO classification in endometrial hyperplasias [Internet]. Pathol Res Pract. 2012 Dec 15;208(12):708-12. doi: 10.1016/ j.prp.2012.08.009. Epub 2012 Oct 6. PMID: 23044462. DOI: https://doi.org/10.1016/j.prp.2012.08.009 Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, Wallwiener M. Endometrial hyperplasia as a risk factor of endometrial cancer [Internet]. Arch Gynecol Obstet. 2022 Jan 10. doi: 10.1007/s00404-021-06380-5. Epub ahead of print. PMID: 35001185. DOI: https://doi.org/10.1007/s00404-021-06380-5 Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. Cancer[Internet].1985;56:403–412.//https://www.ncbi.nlm.nih.gov/pubmed/4005805. DOI: https://doi.org/10.1002/1097-0142(19850715)56:23.0.CO;2-X Presented at the 75th Annual Meeting of the Pacific Coast Obstetrical and Gynecological Society [Internet], Victoria, BC, Canada, Oct. 15-19, 2008. // https://www.ajog.org/ article/S0002-9378(09)00223-3/abstract. Augustin GT et al. Histopathological, Immunohistochemical and Therapeutical Assessment of Premalignant Endometrial Lesions in a Hospital Based Series of Cases [Internet]. Maedica. 2016. Vol. 11(2). P. 115. PMID: 28461830 PMCID: PMC5394573 Khaskhachikh DA, Potapov VO, Kukina GO. Differentiated approach to the treatment of endometrial hyperplasia without atypia in women of reproductive age. Current issues of pediatrics, obstetrics and gynecology [Internet]. 2019; 2 (24):149-154. Ukranian DOI: 10.11603/24116-4944.2019.2.10935. DOI: https://doi.org/10.11603/24116-4944.2019.2.10935 Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia [Internet]. Hum Reprod Updat. 2017; 23(2): 232–254. PMCID: PMC5850217 PMID: 27920066. Gromova OL, Potapov VO, Khaskhachykh DA, Finkova OP, Gaponova OV, Kukina GO, Penner KV. Epigenetic profile of endometrial proliferation in the different morphotypes of endometrial hyperplasia [Internet]. Reproductive Endocrinology. 2021; 57: 68-78. DOI: 10.18370/2309-4117.2021.57.68-78. DOI: https://doi.org/10.18370/2309-4117.2021.57.68-78 Laas E, Ballester M, Cortez A.Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia [Internet]. Gynecol Endocrinol. 2015; 31: 282–285. DOI:10.3109/09513590.2014.989981. DOI: https://doi.org/10.3109/09513590.2014.989981 Palcev М. А., Malcev М. А., Аylamazyan E. К., Kvetnoy I. M. & Polyakova V. O. Molekulyarnyye mekhanizmy zabolevaniy reproduktivnoy sistemy. 2017; SPb.: Eco-Vector. Russia. Zaporozhan V.N, Tatarchuk T.F., Dubinina V.G., Kosey N.V. Modern diagnosis and treatment of endometrial hyperplastic processes. Gynecological Endocrinology. 2012; (3): 5-12. Ozdegirmenci O., Kayikcioglu F., Bozkurt U., Akgul M. A., & Haberal A. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecologic and Obstetric Investigation. 2011; 72 (1): 10-14. DOI: https://doi.org/10.1159/000321390 Al-Sabbagh M, Lam E.W., Brosens J.J. Mechanisms of endometrial progesterone resistance. Mol Cell Endocrinol. 2012; 358: 208–215. DOI: https://doi.org/10.1016/j.mce.2011.10.035 Sletten E, Arnes L, Lyså М, Larsen M, Orbo A. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study[Internet]. BJOG. 2019; 126(7): 936-943. DOI:10.1111/1471-0528.15579. DOI: https://doi.org/10.1111/1471-0528.15579 Paltsev MA, Aylamazyan EKKvetnoy IM, Polyakova VO et al. Molecular mechanisms of diseases of the reproductive system. SPb.:Eko-Vector, 2017; 256. Tatarchuk TF, Kovalenko EP, Filonenko TG, Kubyshkin AV. Expression of receptors to steroid hormones and estrogen and progesterone levels in uterine flushes of women with endometrial hyperplasia. Woman's health. 2011; 6 (62):105-109. Chernukha GE, Dumanovskaya MR. Modern concepts of endometrial hyperpalasia. Obstetrics and gynecology. 2013; 37: 26-32. Gromova OL, Potapov VO, Khaskhachikh DA, Kukina GO, Gaponova OV, Penner KV Receptor status of the endometrium in hyperplastic processes in premenopausal women. Neonatology, surgery and perinatal medicine [Internet]. 2021; 1(39): 33-38. DOI: 10.24061/2413-4260.XI.1.39.2021.5 Ukranian. DOI: https://doi.org/10.24061/2413-4260.XI.1.39.2021.5 Gallos I D, Alazzam M, Clark T, Faraj R, Rosenthal A & Smith P G J Management of Endometrial Hyperplasia. Royal College of Obstetricians & Gynaecologists. Retrieved from. RCOG/BSGE Green-top Guideline [Internet]. 2016:67 https://www.rcog.org.uk/en/ guidelines-research-services/ guidelines/. Behnamfar F, Ghahiri A, & Tavakoli M. Levonorgestrelreleasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia [Internet]. Journal of Research in Medical sciences: the Official Journal of Isfahan University of Medical Sciences. 2014; 19 (8): 686-690. Dolapcioglu K, Boz A & Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study [Internet]. Clinical and Experimental Obstetrics & Gynecology. 2013; 40 (1): 122-126. PMID: 23724525. Orbo A, Vereide A B, Arnes, M, Pettersen I & Straume B. Levonorgestrel-impregnated intrauterine device as tretment for endometrial hyperplasia: a national multicentre randomised trial [Internet]. British Journal of Obstetrics and Gynecology. 2014; 121: 477-486. doi: 10.1111/1471-0528.12499. DOI: https://doi.org/10.1111/1471-0528.12499 Doherty M T, Sanni O B, Coleman H G, Cardwell CR, McCluggage W G, Quinn D & McMenamin U C. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and metaanalysis. PloS One. 2020; 15 (4). e0232231.https://doi.org/10.1371/ journal.pone.0232231. DOI: https://doi.org/10.1371/journal.pone.0232231 Khaskhachikh DA, Potapov VO, Kukina GO. Differentiated approach to the treatment of endometrial hyperplasia without atypia in women of reproductive age. Current issues of pediatrics, obstetrics and gynecology [Internet]. 2019; 2(24): 149-154. DOI: 10.11603/ 24116-4944.2019.2.10935 Ukranian. de Groot JS, Ratze MA, van Amersfoort M, Eisemann T, Vlug EJ, Niklaas MT, Chin SF, Caldas C, van Diest PJ, Jonkers J, de Rooij J, Derksen PW. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. J Pathol. [Internet]. 2018 Aug;245(4):456-467. doi: 10.1002/path.5099. Epub 2018 Jun 20. PMID: 29774524; PMCID: PMC6055824. DOI: https://doi.org/10.1002/path.5099 Maker A, Gumbiner BM. Reconstitution of the full transmembrane cadherin-catenin complex. [Internet]. Protein Expr Purif. 2022 May;193:106056. doi: 10.1016/j.pep.2022. 106056. Epub 2022 Jan 18. PMID: 35063654. DOI: https://doi.org/10.1016/j.pep.2022.106056 Gul IS, Hulpiau P, Saeys Y, van Roy F. Evolution and diversity of cadherins and catenins. [Internet]. Exp Cell Res. 2017 Sep 1;358(1):3-9. doi: 10.1016/j.yexcr.2017.03.001. Epub 2017 Mar 6. PMID: 28268172. DOI: https://doi.org/10.1016/j.yexcr.2017.03.001 Blaschuk OW. Potential Therapeutic Applications of N-Cadherin Antagonists and Agonists. [Internet]. Front Cell Dev Biol. 2022 Mar 3;10:866200. doi: 10.3389/fcell.2022. 866200. PMID: 35309924; PMCID: PMC8927039. DOI: https://doi.org/10.3389/fcell.2022.866200 van der Putten LJM, van Hoof R, Tops BBJ, Snijders MPLM, van den Berg-van Erp SH, van der Wurff AAM, Bulten J, Pijnenborg JMA, Massuger LFAG. Molecular profiles of benign and (pre)malignant endometrial lesions. [Internet]. Carcinogenesis. 2017 Mar 1;38(3): 329-335. doi: 10.1093/carcin/bgx008. PMID: 28203752. DOI: https://doi.org/10.1093/carcin/bgx008 Сілкова ОВ, Лобач НВ. Медична інформатика: навчальний посібник. Полтава: 2016. 262 с. Decree of the Ministry of Health of Ukraine dated 05.05.2021 No. 869 "On the approval of the Unified Clinical Protocol for Primary, Secondary (Specialized), Tertiary (Highly Specialized) Medical Assistance "Hyperplasia Endometriya". Ukrainian.